Countries covered: United States
This updated 3rd edition of Marketdata's pioneering business analysis of this little researched $812 million market is a timely investigation, considering newly revised goals of the US Surgeon General for the "Healthy People 2010" program. Nearly 25% of American adults still smoke—the "hard core" segment. The smoking cessation market has been transformed, shifting from a retail emphasis to a more medical approach. OTC kits, devices, hypnosis seminars, etc. are in decline, while prescription nicotine gum, new drugs (Zyban), and 4 nicotine patches (previously by Rx but now all over-the-counter) are becoming more significant.
The study examines markets for: nicotine gum, patches, drugs, nasal sprays and inhalers, as well as profiles of all major commercial and non-profit organizations with cessation programs/services (Smoke Stopper, Smokenders, Smokeless, Addiction Mgmt. Systems, Amer. Lung Assn., Amer. Cancer Society, etc.). Market size from 1984-2004F. Also provides extensive smoker demographics, analysis of the role of Internet-based, MD, and pharmacist counseling, as well as a status report of corporate smoking restrictions and programs and the anti-smoking regulatory/social environment.
Related Reports:
Opportunities in Menopausal Treatments: Will New Therapies Overtake Hormone Replacement?
Prescription Drug Wholesaling in the US - Industry Risk Rating Report
U.S. Injectable Drug Pipeline
HIV Market Forecast
Forecast Insight: HIV - Cross-Class Fixed Dose Combinations Drive Continued Growth
Asthma and COPD Market Forecast
Commercial Insight: Asthma & COPD - On the verge of generic entry
Pharmaceutical Preparation Manufacturing Industry in the U.S. and its International Trade [Q2 2009 Edition]
SAS Optimizes Drug Launch Through Improved Physician Targeting
Forecast Insight: Fibromyalgia - Regulatory caution threatens EU market expansion
|
(0 items)
